CSL (OTCMKTS:CSLLY) Shares Gap Down – Here’s What Happened

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $31.70, but opened at $30.23. CSL shares last traded at $31.67, with a volume of 482 shares changing hands.

Analyst Ratings Changes

A number of research firms have recently issued reports on CSLLY. Jefferies Financial Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Five analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

CSL Stock Performance

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. The business’s 50-day moving average is $25.03 and its 200 day moving average is $24.10.

About CSL

CSL Limited (OTCMKTS:CSLLY) is an Australian biotechnology company that develops, manufactures and supplies medicines and vaccines. Founded in 1916 as the Commonwealth Serum Laboratories, the company was privatized in 1994 and has grown into a global provider of specialized biopharmaceutical products.

CSL’s principal businesses include CSL Behring, which develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders and other serious medical conditions; CSL Seqirus, which produces influenza and other vaccines; and CSL Vifor, which focuses on therapies for iron deficiency, kidney disease and related conditions.